FGL1 and cancer: Another study recently found that FGL1 is an important component of the FGL1-LAG-3 pathway that promotes the growth of malignant tumors, suggesting that the double blockade of FGL1 and PD-1/PD-L1 could become a therapeutic alternative for patients for whom anti-PD therapy is ineffective [18].